 Cyclooxygenase 2 Inhibitors
"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
| Descriptor ID |
D052246
|
| MeSH Number(s) |
D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500
|
| Concept/Terms |
Cyclooxygenase 2 Inhibitors- Cyclooxygenase 2 Inhibitors
- 2 Inhibitors, Cyclooxygenase
- Inhibitors, Cyclooxygenase 2
- COX2 Inhibitors
- Inhibitors, COX2
- Cyclooxygenase-2 Inhibitors
- Inhibitors, Cyclooxygenase-2
- COX-2 Inhibitors
- COX 2 Inhibitors
- Inhibitors, COX-2
- Coxibs
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 3 | 3 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.
-
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.
-
Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
-
Montrose DC, Zhou XK, McNally EM, Sue E, Yantiss RK, Gross SS, Leve ND, Karoly ED, Suen CS, Ling L, Benezra R, Pamer EG, Dannenberg AJ. Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden. Cancer Prev Res (Phila). 2016 Sep; 9(9):721-31.
-
Choe KS, Liauw SL. Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther. 2013 Feb; 13(2):115-7.
-
Sherid M, Ehrenpreis ED. Types of colitis based on histology. Dis Mon. 2011 Sep; 57(9):457-89.
-
Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug; 12(4):258-66.
-
Whelan CT, Kaboli P, Zhang Q, Siddique J, Ye S, Meltzer DO. Upper gastrointestinal hemorrhage: have new therapeutics made a difference? J Hosp Med. 2009 Sep; 4(7):E6-10.
-
Apfelbaum JL, Desjardins PJ, Brown MT, Verburg KM. Multiple-day efficacy of parecoxib sodium treatment in postoperative bunionectomy pain. Clin J Pain. 2008 Nov-Dec; 24(9):784-92.
-
Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55.
-
Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, Dougherty U, Tretiakova M, Samarel A, Cohen G, Wang J, Moore C, Wali R, Holgren C, Joseph L, Fichera A, Li YC, Bissonnette M. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer. 2008; 60(3):389-400.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|